Five takeaways:
1. Stryker has recently seen a “significant rise” in new installations of its Mako Total Knee platform.
2. The company anticipates solid robot sales in 2019 at hospitals, as well as heightened surgeon interest in orthopedic robotic programs.
3. Stryker management is hopeful about gaining regulatory approvals for the company’s total knee products in China and Japan this year.
4. The wide range of products in Stryker’s portfolio is expected to shield the company from any significant sales shortfall during economic downturns.
5. Stryker’s long-term earnings growth rate is promising, at 10 percent.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.